Alloplex Biotherapeutics has said it now plans to initiate a Phase II trial in early 2025.
Featured
-
Advancing Cellular Therapies: Alloplex’s SUPLEXA Platform Poised to Address Solid Tumor Challenges
Read More -
Naturally Occurring Immune Cells may push through where CAR T cells fall short, reports Genetic Engineering and Biotechnology News
Read More -
Dr. Borriello guest interview on Vial’s ‘first in human’ podcast
Read More
Media Coverage on Alloplex
Date
Categories
Date
Categories
- October 31, 2024
Alloplex’s cancer immunotherapy shows promise in Phase I trial
- October 31, 2024
Alloplex Biotherapeutics Plans Phase II Cell Therapy Trial in Colorectal Cancer
Alloplex Biotherapeutics on Thursday said it will submit an investigational new drug application to the US Food and Drug Administration to begin a Phase II trial of its autologous peripheral blood mononuclear cell (PBMC)-derived cellular therapy, Suplexa, with immune checkpoint inhibitors in certain...
- October 31, 2024
Breakthrough Australian Cancer trial: retraining immune cells offers new hope for patients
In a remarkable development for cancer research, Australian patients with advanced-stage cancer have benefited from SUPLEXA, a personalised treatment that trains the patient’s own immune cells to fight cancer.
- September 27, 2024
Advancing Cellular Therapies: Alloplex’s SUPLEXA Platform Poised to Address Solid Tumor Challenges
In a recent interview with Immuno-Oncology Insights, Dr. Frank Borriello, CEO of Alloplex Biotherapeutics, discussed the potential of Alloplex’s SUPLEXA platform—a novel, autologous, non-engineered cellular therapy designed to treat solid tumors. Solid tumors have remained a significant challeng...
- January 10, 2024
Naturally Occurring Immune Cells may push through where CAR T cells fall short, reports Genetic Engineering and Biotechnology News
Genetic Engineering & Biotechnology News recently published a feature story entitled ‘Immune Cell Therapy May Become More Naturalistic'.
- October 24, 2023
Dr. Borriello guest interview on Vial’s ‘first in human’ podcast
Dr. Borriello on ‘first in human’ podcast by Vial
Frank Borriello, the mind behind SUPLEXA cell therapy, and the CEO and founder of Alloplex Biotherapeutics recently appeared as a guest on the ‘First In Human’ podcast by Vial.
- April 25, 2023
Alloplex Biotherapeutics SUPLEXA cells represent a new type of autologous adoptive cellular therapy for cancer
by Immuno-Oncology Insights, Full Article Behind Paywall
Immuno-Oncology Insights Magazine 2023; 4(3), 89–104 DOI: 10.18609/ioi.2022.013 Alloplex Commentary: SUPLEXA immunotherapeutic cells show promise in stabilizing metastatic cancer without adverse events in a Phase 1 trial, indicating potential as a personalized multi-cancer therapy.
- August 20, 2021
Korean drugmakers seek global collaboration for open innovation
Korean pharmaceutical firms, like Daewoong and Hanall, are embracing open innovation, partnering with global companies, including U.S. biotech firm Alloplex, to accelerate drug development and enhance their competitiveness in international markets.
- August 20, 2021
Daewoong Pharmaceutical and Hanall Biopharma invest in Alloplex Biotherapeutics to develop anti-cancer immune treatment
By Korea IT Times, Global News Network
Daewoong Pharmaceutical and Hanall Biopharma announced that they had made a joint investment worth $1 million in Alloplex Biotherapeutics, a Boston-based drug development company. The two companies plan to work together to develop Alloplex’s anti-cancer immune cell treatment.
- August 20, 2021
Alloplex in the News ‘Daewoong and HanAll invest in Alloplex’
This week, BioSpectrum Asia reported the news of Daewoong Pharmaceutical Co., Ltd. and HanAll BioPharma Co., Ltd.’s investment in Alloplex Biotherapeutics, Inc. this week. Here is a copy of that coverage.
- July 31, 2019
Speaker Interview with Frank Borriello at 2nd Annual Next Gen Immuno-Oncology Congress
By Markets and Markets Conferences
An Interview with Frank Borriello, CEO, Alloplex Biotherapeutics about advances in immuno-oncology and current challenges that need immediate attention. This interview took place at the MarketsandMarkets Next Gen Immuno-Oncology Congress, in Philadelphia, USA.